Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
<h4>Objective</h4>Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes.<h4>Design</h4>Systematic review and me...
Saved in:
Main Authors: | Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0166125 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01) -
Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01) -
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
by: E. V. Kovalenko, et al.
Published: (2021-02-01) -
Effects of sodium-glucose cotransport-2 inhibitors treatment in patients with pulmonary hypertension
by: Mohammed Obeidat, et al.
Published: (2025-06-01) -
Effect of sodium-glucose cotransporter 2 inhibitors on ventricular function in systemic right ventricular failure
by: Lorna Swan, et al.
Published: (2025-07-01)